Ketamine is a new wave in the psychotherapy domain. This FDA approved medication is being explored for the treatment of psychiatric disorders. This brings only one question to mind, is ketamine the better option or other psychedelic therapies are a better choice?
The question remains somewhat answered, considering that a lot of other psychedelics are also currently being experimented with. The most common one is psilocybin. This mushroom-based psychedelic compound has become quite usual to use among younger generations to experience the effects first-hand.
But, how effective or different are these psychedelics or compounds when compared to ketamine? We discovered the similarities and the vast differences between ketamine vs. psilocybin and other compounds.
What is Ketamine?
Ketamine acts as a dissociative anesthetic by blocking NMDA receptors in the brain, which alters perception, pain, and mood. Researchers originally developed it for surgical anesthesia, but clinicians now use it in sub-anesthetic doses to treat mental health conditions like treatment-resistant depression and PTSD.
It produces rapid antidepressant effects by increasing glutamate activity and promoting neuroplasticity. It induces a dissociative state that helps patients process emotions and trauma more effectively during therapy.
Other Psychedelics Being Considered for Therapies
Psychedelics have been around for a long time, and people have used them in therapy for years. While some still have doubts about these treatments, their use continues to grow. Below are some well-known psychedelics currently being studied and used in mental health care.
- Psilocybin: Introduced to modern medicine by Alfred Hofmann, psilocybin and psilocin were the two active compounds discovered by the same name of the mushroom species. As time went by more research has come up that shows that psilocybin reduced recidivism rates (below 40%) among prisoners.
- MDMA (3,4-Methylenedioxymethamphetamine): MDMA also known as Ecstacy and Molly was synthesized by Alexander Shulgin. Later, he introduced it to Leo Zeff, a psychotherapist, who introduced MDMA to over 4,000 therapists, who used it for couples counseling, trauma therapy, and personal growth.
- LSD (Lysergic Acid Diethylamide): LSD synthesized by Alfred Hofmann slowly gained popularity in psychiatry as a tool for psychotherapy. A study showed that Dr. Humphry Osmond treated alcoholics with LSD and reported that 40–45% of patients remained sober for over a year.
- DMT (N,N-Dimethyltryptamine) / Ayahuasca: Even though Richard Manske first synthesized DMT, it had since been identified in many plants and seeds naturally. DMT was later studied as a model for psychosis and tested in schizophrenia patients, though this theory was later debunked.
- Mescaline (Peyote/San Pedro Cactus): Mescaline, a naturally occurring psychedelic alkaloid found in cacti. The compound was explored for psychiatric therapy, aiding patients in accessing repressed memories and addressing anxiety. It also has roots of use by the Indigenous cultures in the Americas.
- Emerging Compounds: There are some special compounds, such as 5-MeO-DMT and Ibogaine that are currently emerging as therapy-use psychedelics. Researchers are experimenting with one compound derived from toad venom for anxiety and depression, while they are testing the other for opioid addiction—though its cardiac risks limit clinical adoption.
Ketamine Therapy Vs. Psilocybin
Mental health professionals use both ketamine and psilocybin in therapy, but the two substances differ greatly in how they work, how long they last, and the experiences they create. Understanding these differences can help determine which option may be better for specific needs.
How ketamine and psilocybin differ:
Drug Classification
- Ketamine is a dissociative anesthetic with psychedelic effects. It’s a Schedule III drug, meaning it’s legal for medical use and often used in clinical settings. It works mainly through the brain’s glutamate system.
- Psilocybin, found in “magic mushrooms,” is a classic psychedelic and a Schedule I substance, meaning it’s illegal federally but allowed in some states. It affects serotonin pathways.
Mechanism of Action
- Ketamine blocks NMDA receptors, which boosts glutamate and increases neuroplasticity—helping form new brain connections quickly.
- Psilocybin mimics serotonin by activating 5HT2A receptors. This leads to shifts in perception and emotion, often creating deep emotional insights and longer-lasting change.
Duration of Effects
- Ketamine kicks in within 10 minutes (IV) and lasts 40–90 minutes, making it ideal for shorter therapy sessions.
- Psilocybin takes 30–60 minutes to start and lasts 3–6 hours, requiring a longer guided session.
Therapeutic Applications
- Ketamine offers fast relief from depression, suicidality, and anxiety—especially in urgent or treatment-resistant cases.
- Psilocybin provides lasting improvements for depression, addiction, and end-of-life anxiety. It encourages deep self-reflection during therapy.
Subjective Experience
- Ketamine creates a dissociative state—many describe it as calming and “out-of-body,” with less visual intensity.
- Psilocybin produces vivid visuals, emotional breakthroughs, and often mystical or spiritual experiences.
Neurotransmitter Activity
| Neurotransmitter | Ketamine | Psilocybin |
|---|---|---|
| Glutamate | High | Moderate |
| Serotonin | Moderate | High |
| Dopamine | Moderate | Moderate |
| GABA | Moderate | High |
Clinical Efficacy
- Ketamine can reduce symptoms within hours, but its effects often wear off in days or weeks unless treatment continues.
- Psilocybin can produce lasting benefits after just one or two sessions, with results sometimes lasting six months.
Safety Profile
- Ketamine may raise blood pressure and cause bladder issues with frequent use.
- Psilocybin has low physical risk but may cause anxiety or paranoia if taken without proper guidance.
Legal Status
- Ketamine is approved for medical use across the U.S. and widely available in clinics.
- Psilocybin remains federally illegal but is decriminalized or legal for therapeutic use in some states, like Oregon.
Therapeutic Outcome Correlation
- Studies show that the subjective experience of ketamine contributes to about 5–10% of its antidepressant effect.
- With psilocybin, the experience plays a larger role—about 24% of therapeutic improvement is linked to the psychedelic journey itself.
Ketamine-Assisted Psychotherapy Vs. MDMA
There are distinct differences between ketamine-based therapies and MDMA. Generally, most people don’t have the broader knowledge to pursue what may be right for them. However, as a therapist, you can research, gain deeper insight, and confidently offer the best therapy according to their needs.
What are uncommon between ketamine vs. MDMA:
Ketamine and MDMA are classified differently and have distinct legal statuses
Ketamine is a dissociative anesthetic with psychedelic properties, legally designated as a Schedule III substance in the U.S., making it available for clinical use.
MDMA, often referred to as an empathogen or entactogen, is classified as Schedule I, indicating a high potential for abuse and no currently accepted medical use. However, the FDA has granted it Breakthrough Therapy designation for PTSD.
Ketamine and MDMA affect the brain through different mechanisms
| Factors | Ketamine | MDMA |
|---|---|---|
| Primary Target | NMDA glutamate receptor antagonist | Serotonin (5-HT) and oxytocin release; adrenergic system activation |
| Neurotransmitters | Increases glutamate, GABA, dopamine, serotonin | Surges serotonin, oxytocin, and norepinephrine |
| Neuroplasticity | Rapid synaptic growth via BDNF signaling | Enhances emotional memory processing and social bonding |
Ketamine and MDMA are both used therapeutically but for different conditions
Ketamine is widely used for treatment-resistant depression (TRD), suicidality, chronic pain, and PTSD, often producing rapid results within hours that can last days to weeks. MDMA is primarily investigated for PTSD, social anxiety (especially in autism), and couples therapy, with up to 71% of patients showing no longer qualifying for PTSD after just three sessions.
The route of administration and experiential timeline differ between ketamine and MDMA
| Aspects | Ketamine | MDMA |
|---|---|---|
| Routes | IV/IM injection, nasal spray, oral lozenge | Oral tablets (taken in clinical settings) |
| Onset/Duration | Effects in 5–10 minutes; lasts 40–90 minutes | Effects in 30–45 minutes; lasts 3–5 hours |
| Subjective Effects | Dissociation, calmness, “out-of-body” sensations | Emotional openness, empathy, reduced fear, enhanced introspection |
Ketamine and MDMA each have unique safety profiles and risks
| Concerns | Ketamine | MDMA |
|---|---|---|
| Acute Risks | Nausea, hypertension, dissociation | Hyperthermia, dehydration, jaw clenching |
| Chronic Risks | Bladder toxicity, rare dependency | Serotonin depletion, neurotoxicity (with high/recreational doses) |
| Overdose Potential | Low in clinical settings; respiratory depression (high doses) | Hyponatremia, organ failure (rare with therapeutic doses) |
Clinical use protocols for ketamine and MDMA are structured differently
Ketamine is often administered weekly or biweekly, frequently alongside CBT or mindfulness-based therapy. MDMA-assisted therapy typically includes three guided sessions, spaced several weeks apart, and is combined with trauma-focused psychotherapy such as prolonged exposure.
Ketamine is currently approved and accessible; MDMA is still under review
Ketamine is FDA-approved as an anesthetic and as esketamine (Spravato®) for depression. It’s available in over 500 U.S. clinics. MDMA has completed Phase 3 clinical trials with a likely FDA submission by 2025 and is currently only available through clinical trials like those sponsored by MAPS.
Ketamine and MDMA impact the brain differently on a neurobiological level
Ketamine rapidly triggers synaptic plasticity through glutamate signaling and has anti-inflammatory properties, lowering depression-linked cytokines. MDMA promotes oxytocin release, supporting trust and emotional processing, and reduces amygdala hyperactivity, which aids in trauma processing.
Clinical studies show strong outcomes for both ketamine and MDMA
| Metrics | Ketamine | MDMA |
|---|---|---|
| Response Rate | 50–70% in TRD patients within 24 hours | 46% PTSD remission rate post-therapy |
| Suicidality | 50% reduction in suicidal ideation within 4 hrs | Effect size of d=0.7 in PTSD trials (large vs. placebo) |
The future of ketamine and MDMA includes new formats and broader access
Ketamine’s future includes at-home treatment models (oral lozenges + telehealth) and longer-acting injectables currently in development. MDMA’s future likely includes combined treatment modalities (e.g., with DBT or somatic therapies), and wider international acceptance, as seen in Australia’s 2023 approval for PTSD.
KAP Vs. LSD
Ketamine-Assisted Psychotherapy and LSD are common on only one ground, they are both psychedelics that are being used in mental health therapeutic approaches. KAP is still very widespread compared to LSD and there are good reasons why.
The reason for such differences are:
Ketamine and LSD are classified differently and have distinct legal statuses
Ketamine is a dissociative anesthetic with psychedelic properties. It’s classified as a Schedule III drug in the U.S., making it legal for medical use and widely available in clinics. LSD (lysergic acid diethylamide), on the other hand, is a classical psychedelic that works primarily as a serotonin 5-HT2A receptor agonist. It remains a Schedule I substance, indicating no accepted medical use under current U.S. law.
Ketamine and LSD work on different brain pathways and chemicals
Ketamine
- Primary Target: NMDA glutamate receptor antagonist
- Neurotransmitters: Increases glutamate, GABA, dopamine, and serotonin
- Neuroplasticity: Stimulates rapid synaptic growth via BDNF, improving neural connectivity
LSD
- Primary Target: Serotonin 5-HT2A receptor agonist
- Neurotransmitters: Modulates serotonin, dopamine, and glutamate
- Neuroplasticity: Disrupts the Default Mode Network (DMN), enhancing emotional and cognitive flexibility
Ketamine and LSD are being studied for different therapeutic purposes
Ketamine is used for treatment-resistant depression (TRD), suicidality, and chronic pain. It provides rapid relief—sometimes within hours—with effects lasting days to weeks. Esketamine, a derivative, is FDA-approved for TRD. LSD is being researched for anxiety, depression, addiction, and existential distress. Though its clinical research is still in early phases, studies show sustained benefits lasting weeks to months, even after just 1–2 sessions.
Ketamine and LSD differ in how they are administered and how long they last
Ketamine
- Routes: IV/IM injection, nasal spray, or oral lozenge
- Onset/Duration: Effects begin within 5–10 minutes and last 40–90 minutes
- Subjective Effects: Dissociation, calmness, and “out-of-body” sensations
LSD
- Routes: Taken orally via blotter paper or liquid
- Onset/Duration: Effects take 30–60 minutes to begin and can last 8–12 hours
- Subjective Effects: Intense visual hallucinations, ego dissolution, and mystical-type experiences
Each drug comes with its own safety considerations and risks
Ketamine
- Acute Risks: Nausea, elevated blood pressure, dissociation
- Chronic Risks: Rare bladder toxicity and dependency in long-term use
- Toxicity: Low overdose risk in clinical environments
LSD
- Acute Risks: Can trigger anxiety, paranoia, or “bad trips” without proper support
- Chronic Risks: Rare cases of Hallucinogen Persisting Perception Disorder (HPPD), and psychological distress
- Toxicity: Considered non-toxic; no known fatal overdoses
Ketamine and LSD produce distinct neurobiological effects
Ketamine works by triggering a glutamate surge that leads to BDNF release and rapid synaptic plasticity. It also has anti-inflammatory effects, reducing depression-linked cytokines. LSD reduces activity in the brain’s Default Mode Network, supporting introspective states. It also boosts global connectivity across brain regions, which can enhance empathy, creativity, and emotional insight.
Clinical use protocols vary between ketamine and LSD
Ketamine is often used in weekly or biweekly sessions, and therapy is typically combined with CBT or mindfulness-based interventions. LSD-assisted therapy usually involves 1–2 sessions, but requires substantial preparation and integration time. It is often paired with psychoanalytic or transpersonal approaches.
Ketamine and LSD show promising—but different—clinical outcomes
Ketamine
- Response Rate: 50–70% in TRD patients within 24 hours
- Suicidality: Reduces suicidal ideation by 50% within 4 hours
LSD
- Anxiety Reduction: 33% remission rate in patients facing life-threatening illness
- Addiction: Early studies show 40–45% sobriety in alcoholics post-treatment
Each substance offers unique research insights for future mental health treatments
Ketamine
- Allows for real-time dose adjustments to fine-tune therapeutic experiences.
- Oral lozenges make at-home treatment models and teletherapy more feasible.
LSD
- Shows long-lasting effects, with benefits persisting over a year in some trials.
- Promotes enhanced creativity, problem-solving, and artistic expression during sessions.
Is Ketamine A Better Choice for Your Patients?
Ketamine shows fast-acting, powerful antidepressant effects in treatment-resistant depression (TRD), with response rates of 50 to 72% and remission in up to 52% after 3 to 10 infusions. It significantly reduces suicidal ideation by 63% within two hours, making it a critical intervention for high-risk patients.
- Compared to ECT, ketamine is equally effective but preserves memory and cognitive function.
- Dosing protocols usually start with six IV infusions over three weeks, followed by biweekly maintenance.
- Ideal candidates include those with suicidality, poor SSRI response, and early signs of improvement.
- While safe, long-term use requires monitoring for rare bladder issues.
Ketamine offers both speed and cognitive safety, though access and insurance remain challenges.
Also read: Difference Between Psychedelic and Psycholytic Dosing
Ketamine-Assisted Psychotherapy Is Better
In conclusion, while ketamine and other psychedelics like psilocybin, MDMA, and LSD each offer unique therapeutic pathways, ketamine stands out for its rapid onset, cognitive safety, and proven effectiveness in treatment-resistant cases, especially those involving acute suicidality. As research continues to evolve, ketamine remains a powerful and accessible option for both patients and practitioners.
For patients, if you’re ready to explore the healing potential of Ketamine-Assisted Psychotherapy (KAP), we welcome you to join our supportive KAP groups in a safe, guided setting.
For therapists, elevate your practice with our 6-week KAP Practicum, and begin your journey by attending our free Q&A sessions to learn more about certification and integration into your clinical work.
OUR UPCOMING EVENT
Understanding Ketamine-Assisted Psychotherapy: A Therapist’s Introduction
For therapists and behavioral health clinicians, this 2-hour continuing education course, presented through Widener University, offers an introduction to key considerations in ketamine-assisted psychotherapy. The live interactive webinar takes place on September 18, 2026, from 9:30–11:30 a.m. ET and is designed for social workers, therapists, and other behavioral health clinicians.
Participants will explore:
- Common contraindications and safety considerations
- Which clients may be best suited for ketamine-assisted psychotherapy
- Considerations surrounding other ketamine therapies
The course will be presented by Diane Nachamkin, MSN, CRNP, Nurse Practitioner, and Dr. Sophia Brandstetter, LCSW, PsyD.
